Preparation of a matrix type multiple-unit gastro retentive floating drug delivery system for captopril based on gas formation technique: In Vitro evaluation

AAPS PharmSciTech

Volumn 9, Issue 2, 2008, Pages 612-619

  Meka, Lingam ^a   Kesavan, Bhaskar ^a   Chinnala, Krishna Mohan ^a   Vobalaboina, Venkateswarlu ^a   Yamsani, Madhusudan Rao ^a  

^a KAKATIYA UNIVERSITY   (India)

Author keywords

Captopril; Controlled release; Gastroretentive; Minitablets

Indexed keywords

BICARBONATE; CAPTOPRIL; ETHYL CELLULOSE; EUDRAGIT; EUDRAGIT RS; HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL 6000; MAGNESIUM STEARATE; METHOCEL E15LV; MICROCRYSTALLINE CELLULOSE; UNCLASSIFIED DRUG; ACRYLIC ACID RESIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG CARRIER; POLYMER; POLYMETHACRYLIC ACID DERIVATIVE;

ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG RETENTION; DRUG SOLUBILITY; DRUG STORAGE; IN VITRO STUDY; MATRIX TABLET; MEAN RESIDENCE TIME; STORAGE TEMPERATURE; TABLET COMPRESSION; TABLET FORMULATION; ARTIFICIAL MEMBRANE; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG FORMULATION; DRUG STABILITY; GAS; HUMAN; HUMIDITY; KINETICS; METABOLISM; METHODOLOGY; MICROCAPSULE; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; SOLUBILITY; STOMACH; STOMACH EMPTYING; TABLET; TEMPERATURE;

ACRYLIC RESINS; ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPSULES; CAPTOPRIL; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; GASES; GASTRIC EMPTYING; HUMANS; HUMIDITY; KINETICS; MEMBRANES, ARTIFICIAL; POLYMERS; POLYMETHACRYLIC ACIDS; SODIUM BICARBONATE; SOLUBILITY; STOMACH; TABLETS; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE;

EID: 51449117204     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-008-9090-4     Document Type: Article

References (48)

1. S. Desai, and S. Bolton. A floating controlled-release drug delivery systems: In vitro-in vivo evaluation. Pharm. Res. 10: 1321-1325 (1993).
2. H. R. Chueh, H. Zia, and C. T. Rhodes. Optimization of sotalol floating and bioadhesive extended release tablet formulations. Drug Dev. Ind. Pharm. 21: 1725-1747 (1995).
3. V. Iannuccelli, G. Coppi, M. T. Bernabei, and R. Cameroni. Air compartment multiple-unit system for prolonged gastric residence. Part I. Formulation study. Int. J. Pharm. 174: 47-54 (1998).
4. L. Whitehead, J. T. Fell, J. H. Collett, H. L. Sharma, and A. M. Smith. Floating dosage forms: An in vivo study demonstrating prolonged gastric retention. J. Control. Release. 55: 3-12 (1998).
5. B. N. Singh, and K. H. Kim. Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. J. Control. Release. 63: 235-259 (2000).
6. S. Arora, J. Ali, A. Ahuja, R. K. Khar, and S. Baboota. Floating drug delivery systems: A review. AAPS Pharm. Sci. Technol. 6: E372-E390 (2005), article 47.
7. P. L. Bardonnet, V. Faivre, W. J. Pugh, J. C. Piffaretti, and F. Falson. Gastroretentive dosage forms: Overview and special case of Helicobacter pylori. J. Contro. Release. 111: 1-18 (2006).
8. N. Rouge, P. Buri, and E. Doelker. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int. J. Pharm. 136: 117-139 (1996).
9. Y. Sato, Y. Kawashima, H. Takeuchi, and H. Yamamoto. In vitro and in vivo evaluation of riboflavin-containing microballoons for a floating controlled drug delivery system in healthy humans. Int. J. Pharm. 275: 97-107 (2004).
10. M. P. Cooreman, P. Krausgrill, and K. J. Hengels. Local gastric and serum amoxycillin concentrations after different oral application forms. Antimicrob. Agents Chemother. 37: 1506-1509 (1993).
11. L. Yang, J. Eshraghi, and R. Fassihi. A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: In vitro evaluation. J. Control. Release. 57: 215-222 (1999).
12. R. B. Umamaheshwari, S. Jain, D. Bhadra, and N. K. Jain. Floating microspheres bearing acetohydroxamic acid for the treatment of Helicobacter pylori. J. Pharm. Pharmacol. 55: 1607-1613 (2003).
13. S. K. Jain, A. M. Awasthi, N. K. Jain, and G. P. Agrawal. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: Preparation and in vitro characterization. J. Control. Release. 107: 300-309 (2005).
14. M. Ichigawa, S. Watanabe, and Y. Miyake. A new multiple-unit oral floating dosage system. I. Preparation and in vitro evaluation of floating and sustained-release characteristics. J. Pharm. Sci. 80: 1062-1066 (1991).
15. Y. Kawashima, T. Niwa, H. Takeuchi, T. Hino, and Y. Ito. Preparation of multiple unit hollow microspheres (microballoons) with acrylic resin containing tranilast and their drug release characteristics (in vitro) and floating behavior (in vivo). J. Control. Release. 16: 279-290 (1991).
16. A. Streubel, J. Siepmann, and R. Bodmeier. Multiple unit gastroretentive drug delivery systems: A new preparation method for low density microparticles. J. Microencapsul. 20: 329-347 (2003).
17. R. Talukder, and R. Fassihi. Gastroretentive delivery systems: Hollow beads. Drug Dev. Ind. Pharm. 30: 405-412 (2004).
18. H. Bechgaard, and K. Ladefoged. Distribution of pellets in the gastrointestinal tract. The influence on transit time exerted by the density or diameter of pellets. J. Pharm. Pharmacol. 30: 690-692 (1978).
19. H. Bechgaard, and G. H. Nielson. Controlled release multiple units and single unit doses. Drug Dev. Ind. Pharm. 4: 53-67 (1978).
20. C. Vervaet, L. Baert, and J. P. Remon. Extrusion-spheronization: A literature review. Int. J. Pharm. 116: 131-146 (1995).
21. Y. Sato, Y. Kawashima, H. Takeuchi, and H. Yamamoto. Physicochemical properties to determine the buoyancy of hollow microspheres (microballoons) prepared by the emulsion solvent diffusion method. Eur. J. Pharm. Biopharm. 55: 297-304 (2003).
22. A. Streubel, J. Siepmann, and R. Bodmeier. Floating microparticles based on low density foam powder. Int. J. Pharm. 241: 279-292 (2002).
23. P. Sriamornsak, N. Thirawong, and S. Puttipipatkhachorn. Emulsion gel beads of calcium pectinate capable of floating on the gastric fluid: Effect of some additives, hardening agent or coating on release behavior of metronidazole. Eur. J. Pharm. Sci. 24: 363-373 (2005).
24. F. Atyabi, H. L. Sharma, H. A. H. Mohammad, and J. T. Fell. Controlled drug release from coated floating ion exchange resin beads. J. Contr. Release. 42: 25-28 (1996).
25. B. Y. Choi, H. J. Park, S. J. Hwang, and J. B. Park. Preparation of alginate beads for floating drug delivery system: Effects of CO2 gas-forming agents. Int. J. Pharm. 239: 81-91 (2002).
26. R. K. Ferguson, G. A. Turini, H. R. Brunner, H. Gavras, and D. N. McKinstry. A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet. 1 8015:775-778 (1977) Apr 9.
27. K. L. Duchin, S. M. Singhvi, D. A. Willard, B. H. Migdalof, and D. N. McKinstry. Captopril kinetics. Clin Pharmacol Ther. 31 4:452-458 (1982).
28. N. H. Anaizi, and C. Swenson. Instability of aqueous captopril solutions. Am. J. Health Syst. Pharm. 50: 486-488 (1993).
29. J. Singh, and D. H. Robinson. Controlled release kinetics of captopril form tableted microcapsules. Drug Dev. Ind. Pharm. 14 4:545 (1988).
30. I. R. Wilding, S. S. Davis, M. Bakhshaee, H. N. E. Stevens, R. A. Sparrow, and J. Brennan. Gastrointestinal transit and systemic absorption of captopril from a pulsed release formulation. Pharm. Res. 9: 654-657 (1992).
31. P. R. Sheth, and J. L. Tossounian. The hydrodynamic balanced system (HBS): A novel drug delivery system for oral use. Drug Dev. Ind. Pharm. 10: 313-339 (1984).
32. Y. W. Chien. Potential developments and new approaches in oral controlled-release drug delivery systems. Drug Dev. Ind. Pharm. 9: 1291-1330 (1983).
33. F. Barbeto, S. Morrica, and F. Quaglia. Analysis of ACE inhibitor by high performance liquid chromatography. Farmaco. 49: 457-460 (1994).
34. P. L. Ritger, and N. A. Peppas. A simple equation for description of solute release. I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J. Contr. Release. 5: 23-36 (1987).
35. P. Costa, and J. M. Sousa Lobo. Modelling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13: 123-133 (2001).
36. C. H. M. Jacques, H. B. Hopfenberg, and V. Stannett. Super case II transport of organic vapors in glassy polymers. In H. B. Hopfenberger (ed.), Permeability of Plastic Films and Coatings to Gases, Vapors, and Liquids, Plenum, New York, 1974, pp. 73-86.
37. B. R. Mathews. Regulatory aspects of stability testing in Europe. Drug Dev. Ind. Pharm. 25: 831-856 (1999).
38. J. W. Moore, and H. H. Flanner. Mathematical comparison of curves with an emphasis on in-vitro dissolution profiles. Pharm. Technol. 20: 64-74 (1996).
39. I. Krögel, and R. Bodmeier. Floating or pulsatile drug delivery systems based on coated effervescent cores. Int. J. Pharm. 187: 175-184 (1999).
40. F. Giordano, A. Rossi, R. Bettini, A. Savioli, A. Gazzaniga, and C. S. Novák. Thermal behavior of paracetamol-polymeric excipients mixtures. J. Therm Anal. Cal. 68 2:575-590 (2002).
41. P. Mura, A. Manderioli, G. Bramanti, S. Furlanetto, and S. Pinzauti. Utilization of differential scanning calorimetry as a screening technique to determine the compatibility of ketoprofen with excipients. Int. J. Pharm. 119: 71-79 (1995).
42. T. Dürig, and A. R. Fassihi. Identification of stabilizing and destabilizing effects of excipient-drug interactions in solid dosage form design. Int. J. Pharm. 97 1-3:161-170 (1993).
43. P. Mura, M. T. Faucci, A. Manderioli, G. Bramanti, and L. Ceccarelli. Compatibility study between ibuproxam and pharmaceutical excipients using differential scanning calorimetry, hot-stage microscopy and scanning electron microscopy. J. Pharm. Biomed. Anal. 18: 151-163 (1998).
44. R. Kandarapu, V. Grover, H. P. S. Chawla, and S. Garg. Evaluation of the compatibility of ketorolac tromethamine with selected polymers and common tablet excipients by thermal and isothermal stress testing. S. T. P. Pharma Sci. 11: 449-457 (2001).
45. S. A. Botha, and A. P. Lotter. Compatibility study between naproxen and tablet excipients using differential scanning calorimetry. Drug Dev. Ind. Pharm. 16: 673-683 (1990).
46. C. E. P. Malan, M. M. Villers, and A. P. Lotter. Application of differential scanning calorimetry and high performance liquid chromatography to determine the effects of mixture composition and preparation during the evaluation of niclosamide-excipient compatibility. J. Pharm. Biomed. Anal. 15: 549-557 (1997).
47. I. Ghebre-Sellassie, R. U. Nesbitt, and J. Wang. Eudragit aqueous dispersions as pharmaceutical controlled release coatings. In J. W. McGinity (ed.), Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms, 2nd ed., Marcel Dekker, New York, pp. 267-286.
48. K. H. Bauer, K. Lehmann, H. P. Osterwald, and G. Rothgang. Coated Pharmaceutical Dosage Forms, Medpharm Scientific, Stuttgart, 1998, pp. 63-119.